Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 8/2021

01-08-2021 | Amyotrophic Lateral Sclerosis | Review Article

Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions

Authors: Ambika Shandilya, Sidharth Mehan

Published in: Neurological Sciences | Issue 8/2021

Login to get access

Abstract

The prominent causes for motor neuron diseases like ALS are demyelination, immune dysregulation, and neuroinflammation. Numerous research studies indicate that the downregulation of IGF-1 and GLP-1 signaling pathways plays a significant role in the progression of ALS pathogenesis and other neurological disorders. In the current review, we discussed the dysregulation of IGF-1/GLP-1 signaling in neurodegenerative manifestations of ALS like a genetic anomaly, oligodendrocyte degradation, demyelination, glial overactivation, immune deregulation, and neuroexcitation. In addition, the current review reveals the IGF-1 and GLP-1 activators based on the premise that the restoration of abnormal IGF-1/GLP-1 signaling could result in neuroprotection and neurotrophic effects for the clinical-pathological presentation of ALS and other brain diseases. Thus, the potential benefits of IGF-1/GLP-1 signal upregulation in the development of disease-modifying therapeutic strategies may prevent ALS and associated neurocomplications.
Literature
1.
Underwood LE, Thissen JP, Lemozy S, Ketelslegers JM, Clemmons DR (1994) Hormonal and nutritional regulation of IGF-I and its binding proteins. Hormone Research in Paediatrics 42(4-5):145–151CrossRef
2.
Rinderknecht E, Humbel RE (1978) The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 253(8):2769–2776PubMedCrossRef
3.
Withers DJ, White M (2000) Perspective: the insulin signaling system—a common link in the pathogenesis of type 2 diabetes. Endocrinology 141(6):1917–1921PubMedCrossRef
4.
Clemmons DR (1997) Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev 8(1):45–62PubMedCrossRef
5.
Baragli A, Lanfranco F, Allasia S, Granata R, Ghigo E (2011) Neuroendocrine and metabolic activities of ghrelin gene products. Peptides. 32(11):2323–2332PubMedCrossRef
6.
Vogel T (2013) Insulin/IGF-signalling in embryonic and adult neural proliferation and differentiation in the mammalian central nervous system. Trends in Cell Signaling Pathways in Neuronal Fate Decision, 38-73.
7.
Laviola L, Natalicchio A, Giorgino F (2007) The IGF-I signaling pathway. Curr Pharm Des 13(7):663–669PubMedCrossRef
8.
Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, Greig NH (2003) Glucagon-like peptide-1 decreases endogenous amyloid-β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron. J Neurosci Res 72(5):603–612PubMedCrossRef
9.
10.
Sarkar S, Fekete C, Légrádi G, Lechan RM (2003) Glucagon like peptide-1 (7-36) amide (GLP-1) nerve terminals densely innervate corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res 985(2):163–168PubMedCrossRef
11.
12.
Bassil F, Fernagut PO, Bezard E, Meissner WG (2014) Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Prog Neurobiol 118:1–18PubMedCrossRef
13.
Yin F, Jiang T, Cadenas E (2013) Metabolic triad in brain aging: mitochondria, insulin/IGF-1 signalling and JNK signalling.
14.
Saenger S, Holtmann B, Nilges MR, Schroeder S, Hoeflich A, Kletzl H, Spooren W, Ostrowitzki S, Hanania T, Sendtner M et al (2012) Functional improvement in mouse models of familial amyotrophic lateral sclerosis by pegylated insulin-like growth factor i treatment depends on disease severity. Amyotroph Lateral Scler 13:418–429PubMedCrossRef
15.
Sukhanov S, Higashi Y, Shai SY, Vaughn C, Mohler J, Li Y, Song YH, Titterington J, Delafontaine P (2007) IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 27(12):2684–2690PubMedCrossRef
16.
Hao CN, Geng YJ, Li F, Yang T, Su DF, Duan JL, Li Y (2011) Insulin-like growth factor-1 receptor activation prevents hydrogen peroxide-induced oxidative stress, mitochondrial dysfunction and apoptosis. Apoptosis 16(11):1118–1127PubMedCrossRef
17.
McMorris FA, McKinnon RD (1996) Regulation of oligodendrocyte development and CNS myelination by growth factors: prospects for therapy of demyelinating disease. Brain Pathol 6(3):313–329PubMedCrossRef
18.
Grinberg YY, Dibbern ME, Levasseur VA, Kraig RP (2013) Insulin-like growth factor-1 abrogates microglial oxidative stress and TNF-α responses to spreading depression. J Neurochem 126(5):662–672PubMedPubMedCentralCrossRef
19.
Labandeira-Garcia JL, Costa-Besada MA, Labandeira CM, Villar-Cheda B, Rodríguez-Perez AI (2017) Insulin-like growth factor-1 and neuroinflammation. Front Aging Neurosci 9:365PubMedPubMedCentralCrossRef
20.
Dodge JC, Haidet AM, Yang W, Passini MA, Hester M, Clarke J, Roskelley EM, Treleaven CM, Rizo L, Martin H, Kim SH (2008) Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol Ther 16(6):1056–1064PubMedCrossRef
21.
22.
Kim JH, Wu TH, Budde MD, Lee JM, Song SK (2011) Noninvasive detection of brainstem and spinal cord axonal degeneration in an amyotrophic lateral sclerosis mouse model. NMR Biomed 24(2):163–169PubMedCrossRef
23.
van Eijk RP, Jones AR, Sproviero W, Shatunov A, Shaw PJ, Leigh PN, Young CA, Shaw CE, Mora G, Mandrioli J, Borghero G (2017) Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology 89(18):1915–1922PubMedPubMedCentralCrossRef
24.
Haidet-Phillips AM, Hester ME, Miranda CJ, Meyer K, Braun L, Frakes A, Song S, Likhite S, Murtha MJ, Foust KD, Rao M (2011) Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol 29(9):824–828PubMedPubMedCentralCrossRef
25.
26.
27.
28.
29.
30.
Statland JM, Barohn RJ, McVey AL, Katz JS, Dimachkie MM (2015) Patterns of weakness, classification of motor neuron disease, and clinical diagnosis of sporadic amyotrophic lateral sclerosis. Neurol Clin 33(4):735–748PubMedPubMedCentralCrossRef
31.
de Carvalho M, Swash M (2016) Lower motor neuron dysfunction in ALS. Clin Neurophysiol 127(7):2670–2681PubMedCrossRef
32.
33.
34.
Eisen A, Weber M (2001) The motor cortex and amyotrophic lateral sclerosis. Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine 24(4):564–573CrossRef
35.
Kassubek J, Unrath A, Huppertz HJ, Lulé D, Ethofer T, Sperfeld AD, Ludolph AC (2005) Global brain atrophy and corticospinal tract alterations in ALS, as investigated by voxel-based morphometry of 3-D MRI. Amyotroph Lateral Scler 6(4):213–220CrossRef
36.
Nodera H, Takamatsu N, Shimatani Y, Mori A, Sato K, Oda M, Terasawa Y, Izumi Y, Kaji R (2014) Thinning of cervical nerve roots and peripheral nerves in ALS as measured by sonography. Clin Neurophysiol 125(9):1906–1911PubMedCrossRef
37.
Hanyu N, Oguchi K, Yanagisawa N, Tsukagoshi H (1982) Degeneration and regeneration of ventral root motor fibers in amyotrophic lateral sclerosis: morphometric studies of cervical ventral roots. J Neurol Sci 55(1):99–115PubMedCrossRef
38.
Nihei K, McKee AC, Kowall NW (1993) Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients. Acta Neuropathol 86(1):55–64PubMedCrossRef
39.
Spiller KJ, Restrepo CR, Khan T, Dominique MA, Fang TC, Canter RG, Roberts CJ, Miller KR, Ransohoff RM, Trojanowski JQ, Lee VMY (2018) Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy. Nat Neurosci 21(3):329–340PubMedPubMedCentralCrossRef
40.
41.
Muller AP, Fernandez AM, Haas C, Zimmer E, Portela LV, Torres-Aleman I (2012) Reduced brain insulin-like growth factor I function during aging. Mol Cell Neurosci 49(1):9–12PubMedCrossRef
42.
Quesada A, Lee BY, Micevych PE (2008) PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson’s disease. Dev Neurobiol 68:632–644PubMedPubMedCentralCrossRef
43.
Krishnamurthi R, Stott S, Maingay M, Faull RL, McCarthy D, Gluckman P, Guan J (2004) N-terminal tripeptide of IGF-1 improves functional deficits after 6-OHDA lesion in rats. Neuroreport 15:1601–1604PubMedCrossRef
44.
45.
46.
47.
48.
49.
Zeger M, Popken G, Zhang J, Xuan S, Lu QR, Schwab MH, Klaus-Armin Nave, Rowitch D, D’Ercole AJ, Ye P (2007). Insulin-like growth factor type 1 receptor signaling in the cells of oligodendrocyte lineage is required for normal <em>in vivo</em> oligodendrocyte development and myelination 55(4), 400–411. doi:10.1002/glia.20469
50.
51.
52.
During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, Haile CN (2003) Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 9(9):1173–1179PubMedCrossRef
53.
54.
55.
56.
Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, Powers K, Shen H, Egan JM, Sambamurti K, Brossi A, Lahiri DK, Mattson MP, Hoffer BJ, Wang Y, Greig NH (2009 Jan 27) GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A 106(4):1285–1290. https://​doi.​org/​10.​1073/​pnas.​0806720106CrossRefPubMedPubMedCentral
57.
Rinaman L, Comer J (2000). Antagonism of central glucagon-like peptide-1 receptors enhances lipopolysaccharide-induced fever 85(1-3), 101. doi:10.1016/s1566-0702(00)00227-7
58.
Humbert S, Bryson EA, Cordelières FP, Connors NC, Datta SR, Finkbeiner S, Greenberg ME, Saudou F (2002) The IGF-1/Akt pathway is neuroprotective in Huntington’s disease and involves Huntingtin phosphorylation by Akt. Dev Cell 2(6):831–837PubMedCrossRef
59.
Morel GR, Leon ML, Uriarte M, Reggiani PC, Goya RG (2017) Therapeutic potential of IGF-1 on hippocampal neurogenesis and function during aging. Neurogenesis (Austin) 4:e1259709CrossRef
60.
Bilak MM, Kuncl RW (2001) Delayed application of IGF-I and GDNF can rescue already injured postnatal motor neurons. Neuroreport 12(11):2531–2535PubMedCrossRef
61.
Perry T, Greig NH (2005) Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer’s disease. Curr Alzheimer Res 2:377–385PubMedCrossRef
62.
63.
Yang JL, Chen WY, Chen YP, Kuo CY, Chen SD (2016) Activation of GLP-1 receptor enhances neuronal base excision repair via PI3K-AKT-induced expression of apurinic/apyrimidinic endonuclease 1. Theranostics 6(12):2015PubMedPubMedCentralCrossRef
64.
Sobuś A, Machaliński B (2016) Trophic factors in the therapeutic challenge against ALS: current research directions. Update on Amyotrophic Lateral Sclerosis, 213.
65.
Adem A, Ekblom J, Gillberg PG, Jossan SS, Höög A, Winblad B, Aquilonius SM, Wang LH, Sara V (1994) Insulin-like growth factor-1 receptors in human spinal cord: changes in amyotrophic lateral sclerosis. Journal of Neural Transmission/General Section JNT 97(1):73–84CrossRef
66.
Zhu CZ, Auer RN (1994) Intraventricular administration of insulin and IGF-1 in transient forebrain ischemia. J Cereb Blood Flow Metab 14(2):237–242PubMedCrossRef
67.
Araujo DM, Lapchak PA, Collier B, Chabot JG, Quirion R (1989) Insulin-like growth factor-1 (somatomedin-C) receptors in the rat brain: distribution and interaction with the hippocampal cholinergic system. Brain Res 484(1-2):130–138PubMedCrossRef
68.
Cardona-Gómez GP, Chowen JA, Garcia-Segura LM (2000) Estradiol and progesterone regulate the expression of insulin-like growth factor-I receptor and insulin-like growth factor binding protein-2 in the hypothalamus of adult female rats. J Neurobiol 43(3):269–281PubMedCrossRef
69.
Alvarez E, Martínez MD, Roncero I, Chowen JA, García-Cuartero B, Gispert JD, Sanz C, Vázquez P, Maldonado A, De Cáceres J, Desco M (2005) The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 92(4):798–806PubMedCrossRef
70.
Heppner KM, Kirigiti M, Secher A, Paulsen SJ, Buckingham R, Pyke C, Knudsen LB, Vrang N, Grove KL (2015) Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology 156(1):255–267PubMedCrossRef
71.
Hamilton A, Holscher C (2009) Receptors for the insulin-like peptide GLP-1 are expressed on neurons in the CNS Neuroreport 20: 1161
72.
Dupont J, Khan J, Qu BH, Metzler P, Helman L, LeRoith D (2001) Insulin and IGF-1 induce different patterns of gene expression in mouse fibroblast NIH-3T3 cells: identification by cDNA microarray analysis. Endocrinology 142(11):4969–4975PubMedCrossRef
73.
Freude S, Leeser U, Müller M, Hettich MM, Udelhoven M, Schilbach K, Tobe K, Kadowaki T, Köhler C, Schröder H, Krone W (2008) IRS-2 branch of IGF-1 receptor signaling is essential for appropriate timing of myelination. J Neurochem 107(4):907–917PubMed
74.
Guan J (2008) Insulin-like growth factor-1 and its derivatives: potential pharmaceutical application for ischemic brain injury. Recent patents on CNS drug discovery 3(2):112–127PubMedCrossRef
75.
O’Neill BT, Lauritzen HP, Hirshman MF, Smyth G, Goodyear LJ, Kahn CR (2015) Differential role of insulin/IGF-1 receptor signaling in muscle growth and glucose homeostasis. Cell Rep 11(8):1220–1235PubMedPubMedCentralCrossRef
76.
Chesik D, De Keyser J, Wilczak N (2008) Insulin-like growth factor system regulates oligodendroglial cell behavior: therapeutic potential in CNS. J Mol Neurosci 35(1):81PubMedCrossRef
77.
Park SE, Dantzer R, Kelley KW, McCusker RH (2011) Central administration of insulin-like growth factor-I decreases depressive-like behavior and brain cytokine expression in mice. J Neuroinflammation 8(1):1–14
78.
Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I (2002) Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 8:1390–1397PubMedCrossRef
79.
Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH (2002) Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302(3):881–888PubMedCrossRef
80.
Brubaker PL, Drucker DJ (2004) Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145(6):2653–2659PubMedCrossRef
81.
Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R (2002) Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143(11):4397–4408PubMedCrossRef
82.
Green BD, Mooney MH, Gault VA, Irwin N, Bailey CJ, Harriott P, Greer B, O’Harte FP, Flatt PR (2004 Mar) N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. J Endocrinol 180(3):379–388. https://​doi.​org/​10.​1677/​joe.​0.​1800379CrossRefPubMed
83.
Acuna-Goycolea C, van den Pol A (2004) Glucagon-like peptide 1 excites hypocretin/orexin neurons by direct and indirect mechanisms: implications for viscera-mediated arousal. J Neurosci 24:8141–8152PubMedPubMedCentralCrossRef
84.
Gilman CP, Perry T, Furukawa K, Grieg NH, Egan JM, Mattson MP (2003) Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. J Neurochem 87(5):1137–1144PubMedCrossRef
85.
Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O’Regan JP, Deng HX, Rahmani Z (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362(6415):59–62PubMedCrossRef
86.
Radunovic A, Leigh PN (1996) Cu/Zn superoxide dismutase gene mutations in amyotrophic lateral sclerosis: correlation between genotype and clinical features. J Neurol Neurosurg Psychiatry 61(6):565PubMedPubMedCentralCrossRef
87.
Saenger S, Holtmann B, Nilges MR, Schroeder S, Hoeflich A, Kletzl H, Spooren W, Ostrowitzki S, Hanania T, Sendtner M, Metzger F (2012) Functional improvement in mouse models of familial amyotrophic lateral sclerosis by PEGylated insulin-like growth factor I treatment depends on disease severity. Amyotroph Lateral Scler 13(5):418–429PubMedCrossRef
88.
Franz CK, Federici T, Yang J, Backus C, Oh SS, Teng Q, Carlton E, Bishop KM, Gasmi M, Bartus RT, Feldman EL (2009) Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS. Neurobiol Dis 33(3):473–481PubMedCrossRef
89.
Kaspar BK, Lladó J, Sherkat N, Rothstein JD, Gage FH (2003) Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301(5634):839–842PubMedCrossRef
90.
Dobrowolny G, Giacinti C, Pelosi L, Nicoletti C, Winn N, Barberi L, Molinaro M, Rosenthal N, Musarò A (2005) Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol 168(2):193–199PubMedPubMedCentralCrossRef
91.
Lepore AC, Haenggeli C, Gasmi M, Bishop KM, Bartus RT, Maragakis NJ, Rothstein JD (2007) Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res 1185:256–265PubMedPubMedCentralCrossRef
92.
Nagano I, Ilieva H, Shiote M, Murakami T, Yokoyama M, Shoji M, Abe K (2005) Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of amyotrophic lateral sclerosis. J Neurol Sci 235(1-2):61–68PubMedCrossRef
93.
Knippenberg S, Thau N, Schwabe K, Dengler R, Schambach A, Hass R, Petri S (2012) Intraspinal injection of human umbilical cord blood-derived cells is neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis. Neurodegener Dis 9(3):107–120PubMedCrossRef
94.
Sun H, Knippenberg S, Thau N, Ragancokova D, Körner S, Huang D, Dengler R, Döhler K, Petri S (2013) Therapeutic potential of N-acetyl-glucagon-like peptide-1 in primary motor neuron cultures derived from non-transgenic and SOD1-G93A ALS mice. Cell Mol Neurobiol 33(3):347–357PubMedCrossRef
95.
Matsuzaki H, Tamatani M, Mitsuda N, Namikawa K, Kiyama H, Miyake SI, Tohyama M (1999) Activation of Akt kinase inhibits apoptosis and changes in Bcl-2 and Bax expression induced by nitric oxide in primary hippocampal neurons. J Neurochem 73:2037–2046PubMed
96.
Sun X, Huang L, Zhang M, Sun S, Wu Y (2010) Insulin like growth factor-1 prevents 1-mentyl-4-phenylphyridinium-induced apoptosis in PC12 cells through activation of glycogen synthase kinase-3beta. Toxicology 271(1-2):5–12PubMedCrossRef
97.
Tu H, Xu C, Zhang W, Liu Q, Rondard P, Pin JP, Liu J (2010) GABAB receptor activation protects neurons from apoptosis via IGF-1 receptor transactivation. J Neurosci 30(2):749–759PubMedPubMedCentralCrossRef
98.
Zawada WM, Kirschman DL, Cohen JJ, Heidenreich KA, Freed CR (1996) Growth factors rescue embryonic dopamine neurons from programmed cell death. Exp Neurol 140(1):60–67PubMedCrossRef
99.
Li Y, Chigurupati S, Holloway HW, Mughal M, Tweedie D, Bruestle DA, Mattson MP, Wang Y, Harvey BK, Ray B, Lahiri DK (2012) Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS One 7(2):e32008PubMedPubMedCentralCrossRef
100.
Mohiuddin MS, Himeno T, Inoue R, Miura-Yura E, Yamada Y, Nakai-Shimoda H, Asano S, Kato M, Motegi M, Kondo M, Seino Y (2019) Glucagon-like Peptide-1 receptor agonist protects dorsal root ganglion neurons against oxidative insult. J Diabetes Res 2019:1–10CrossRef
101.
102.
Wilkins A, Chandran S, Compston A (2001) A role for oligodendrocyte-derived IGF-1 in trophic support of cortical neurons. Glia 36(1):48–57PubMedCrossRef
103.
Ye P, D’ercole AJ (1999) Insulin-like growth factor I protects oligodendrocytes from tumor necrosis factor-α-induced injury. Endocrinology 140(7):3063–3072PubMedCrossRef
104.
Barres BA, Hart IK, Coles HSR, Burne JF, Voyvodic JT, Richardson WD, Raff M (1992) Cell death and control of cell survival in the oligodendrocyte lineage. Cell 70(1):31–46PubMedCrossRef
105.
Mozell RL, McMorris FA (1991) Insulin-like growth factor I stimulates oligodendrocyte development and myelination in rat brain aggregate cultures. J Neurosci Res 30(2):382–390PubMedCrossRef
106.
107.
Ye P, D’rcole AJ (2006) Insulin-like growth factor actions during development of neural stem cells and progenitors in the central nervous system. J Neurosci Res 83(1):1–6PubMedCrossRef
108.
Hsieh J, Aimone JB, Kaspar BK, Kuwabara T, Nakashima K, Gage FH (2004) IGF-I instructs multipotent adult neural progenitor cells to become oligodendrocytes. J Cell Biol 164(1):111–122PubMedPubMedCentralCrossRef
109.
Gago N, Avellana-Adalid V, Baron-Van Evercooren A, Schumacher M (2003) Control of cell survival and proliferation of postnatal PSA-NCAM+ progenitors. Mol Cell Neurosci 22(2):162–178PubMedCrossRef
110.
111.
Hamilton A, Patterson S, Porter D, Gault VA, Holscher C (2011) Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res 89(4):481–489PubMedCrossRef
112.
Bramanti V, Grasso S, Tomassoni D, Traini E, Raciti G, Viola M, Li Volti G, Campisi A, Amenta F, Avola R (2015) Effect of growth factors and steroid hormones on heme oxygenase and cyclin d1 expression in primary astroglial cell cultures. J Neurosci Res 93:521–529PubMedCrossRef
113.
Rawji KS, Mishra MK, Michaels NJ, Rivest S, Stys PK, Yong VW (2016) Immunosenescence of microglia and macrophages: impact on the ageing central nervous system. Brain 139(3):653–661PubMedPubMedCentralCrossRef
114.
Lalancette-Hébert M, Gowing G, Simard A, Weng YC, Kriz J (2007) Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J Neurosci 27(10):2596–2605PubMedPubMedCentralCrossRef
115.
Nadjar A, Berton O, Guo S, Leneuve P, Dovero S, Diguet E, Tison F, Zhao B, Holzenberger M, Bezard E (2009) IGF-1 signaling reduces neuro-inflammatory response and sensitivity of neurons to MPTP. Neurobiol Aging 30(12):2021–2030PubMedCrossRef
116.
Suh HS, Zhao ML, Derico L, Choi N, Lee SC (2013) Insulin-like growth factor 1 and 2 (IGF1, IGF2) expression in human microglia: differential regulation by inflammatory mediators. J Neuroinflammation 10(1):1–12CrossRef
117.
Ferger AI, Campanelli L, Reimer V, Muth KN, Merdian I, Ludolph AC, Witting A (2010) Effects of mitochondrial dysfunction on the immunological properties of microglia. J Neuroinflammation 7(1):1–10CrossRef
118.
Kettenmann H, Hanisch UK, Noda M, Verkhratsky A (2011) Physiology of microglia. Physiol Rev 91(2):461–553PubMedCrossRef
119.
O’Donnell SL, Frederick TJ, Krady JK, Vannucci SJ, Wood TL (2002) IGF-I and microglia/macrophage proliferation in the ischemic mouse brain. Glia 39(1):85–97PubMedCrossRef
120.
Lee CH, Jeon SJ, Cho KS, Jeon SJ, Cho KS, Moon E, Sapkota A, Jun HS, Ryu JH, Choi JW (2018) Activation of glucagon-like peptide-1 receptor promotes neuroprotection in experimental autoimmune encephalomyelitis by reducing neuroinflammatory responses. Mol Neurobiol 55:3007–3020PubMedCrossRef
121.
Wu HY, Tang XQ, Liu H, Mao XF, Wang YX (2018) Both classic Gs-cAMP/PKA/CREB and alternative Gs-cAMP/PKA/p38β/CREB signal pathways mediate exenatide-stimulated expression of M2 microglial markers. J Neuroimmunol 316:17–22PubMedCrossRef
122.
Malaspina A, Puentes F, Amor S (2015) Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective. Int Immunol 27(3):117–129PubMedCrossRef
123.
Hensley K, Abdel-Moaty H, Hunter J et al. 2006. Primary glia expressing the G93A-SOD1 mutation present a neuroinflammatory in the complete rescue of postnatal motor neurons, Amyotroph Lateral Scler Other Motor
124.
Parakh S, Spencer DM, Halloran MA, Soo KY, Atkin JD (2013) Redox regulation in amyotrophic lateral sclerosis. Oxidative Med Cell Longev 2013:1–12CrossRef
125.
126.
Beers DR, Henkel JS, Zhao W, Wang J, Huang A, Wen S, Liao B, Appel SH (2011) Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain 134(5):1293–1314PubMedPubMedCentralCrossRef
127.
Sta M, Sylva-Steenland RMR, Casula M, De Jong JMBV, Troost D, Aronica E, Baas F (2011) Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation. Neurobiol Dis 42(3):211–220PubMedCrossRef
128.
Xiao Q, Zhao W, Beers DR, Yen AA, Xie W, Henkel JS, Appel SH (2007) Mutant SOD1G93A microglia are more neurotoxic relative to wild-type microglia. J Neurochem 102(6):2008–2019PubMedCrossRef
129.
Swerdlow RH (2012) Alzheimer’s disease pathologic cascades: who comes first, what drives what. Neurotox Res 22(3):182–194PubMedCrossRef
130.
Chiu LY, Ho FM, Shiah SG, Chang Y, Lin WW (2011) Oxidative stress initiates DNA damager MNNG-induced poly (ADP-ribose) polymerase-1-dependent parthanatos cell death. Biochem Pharmacol 81(3):459–470PubMedCrossRef
131.
Li L, El-Kholy W, Rhodes CJ, Brubaker PL (2005) Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia 48(7):1339–1349PubMedCrossRef
132.
Reed JC (1997) Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. In Seminars in hematology (Vol. 34 (4 Suppl 5), 9-19).
133.
Krajewski S, Mai JK, Krajewska M, Sikorska M, Mossakowski MJ, Reed JC (1995) Upregulation of bax protein levels in neurons following cerebral ischemia. J Neurosci 15(10):6364–6376PubMedPubMedCentralCrossRef
134.
Deshmukh M, Johnson EM Jr (1998) Evidence of a novel event during neuronal death: development of competence-to-die in response to cytoplasmic cytochrome c. Neuron 21(4):695–705PubMedCrossRef
135.
136.
137.
138.
139.
Liu J, Wang F (2017) Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front Immunol 8:1005PubMedPubMedCentralCrossRef
140.
Zhou M, Wang CM, Yang WL, Wang P (2013) Microglial CD14 activated by iNOS contributes to neuroinflammation in cerebral ischemia. Brain Res 1506:105–114PubMedPubMedCentralCrossRef
141.
Henkel JS, Beers DR, Zhao W, Appel SH (2009) Microglia in ALS: the good, the bad, and the resting. J NeuroImmune Pharmacol 4(4):389–398PubMedCrossRef
142.
143.
144.
145.
146.
Cui S-S, Feng XB, Zhang BH, Xia ZY, Zhan LY (2020) Exendin-4 attenuates pain-induced cognitive impairment by alleviating hippocampal neuroinflammation in a rat model of spinal nerve ligation. Neural Regen Res 15(7):1333–1339PubMedPubMedCentralCrossRef
147.
Diz-Chaves Y, Toba L, Fandiño J, González-Matías LC, Garcia-Segura LM, Mallo F (2018) The GLP-1 analog, liraglutide prevents the increase of proinflammatory mediators in the hippocampus of male rat pups submitted to maternal perinatal food restriction. J Neuroinflammation 15(1):337PubMedPubMedCentralCrossRef
148.
Kim DS, Choi HI, Wang Y, Luo Y, Hoffer BJ, Greig NH (2017) A new treatment strategy for Parkinson’s disease through the gut–brain axis: the glucagon-like peptide-1 receptor pathway. Cell Transplant 26(9):1560–1571PubMedPubMedCentralCrossRef
149.
Bristol LA, Rothstein JD (1996) Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society 39(5):676–679CrossRef
150.
Olloquequi J, Cornejo-Córdova E, Verdaguer E, Soriano FX, Binvignat O, Auladell C, Camins A (2018) Excitotoxicity in the pathogenesis of neurological and psychiatric disorders: therapeutic implications. J Psychopharmacol 32(3):265–275PubMedCrossRef
151.
Grosskreutz J, Van Den Bosch L, Keller BU (2010) Calcium dysregulation in amyotrophic lateral sclerosis. Cell Calcium 47(2):165–174PubMedCrossRef
152.
153.
154.
Ness JK, Wood TL (2002) Insulin-like growth factor I, but not neurotrophin-3, sustains Akt activation and provides long-term protection of immature oligodendrocytes from glutamate-mediated apoptosis. Mol Cell Neurosci 20(3):476–488PubMedCrossRef
155.
Ness JK, Scaduto RC Jr, Wood TL (2004) IGF-I prevents glutamate-mediated bax translocation and cytochrome C release in O4+ oligodendrocyte progenitors. Glia 46(2):183–194PubMedCrossRef
156.
Gilman CP, Perry TA, Furukawa K, Grieg NH, Egan JM, Mattson MP (2003). Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. 87(5), 1137–1144. doi:10.1046/j.1471-4159.2003.02073.x
157.
158.
Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, Van Den Berg LH (2017) Amyotrophic lateral sclerosis. Nature reviews Disease primers 3(1):1–19
159.
D’Amico E, Factor-Litvak P, Santella RM, Mitsumoto H (2013) Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med 65:509–527PubMedCrossRef
160.
Chico L, Modena M, Gerfo AL, Ricci G, Ienco EC, Ryskalin L, Fornai F, Siciliano G (2017) Cross-talk between pathogenic mechanisms in neurodegeneration: the role of oxidative stress in Amyotrophic Lateral Sclerosis. Arch Ital Biol 155(4):131–141PubMed
161.
Genis L, Dávila D, Fernandez S, Pozo-Rodrigálvarez A, Martínez-Murillo R, Torres-Aleman I (2014) Astrocytes require insulin-like growth factor I to protect neurons against oxidative injury. F1000Research, 3.
162.
163.
Duarte AI, Santos P, Oliveira CR, Santos MS, Rego AC (2008) Insulin neuroprotection against oxidative stress is mediated by Akt and GSK-3β signaling pathways and changes in protein expression. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1783(6):994–1002CrossRef
164.
Wooten MW (1999) Function for NF-kB in neuronal survival: regulation by atypical protein kinase C. J Neurosci Res 58(5):607–611PubMedCrossRef
165.
Carro E, Trejo JL, Gerber A, Loetscher H, Torrado J, Metzger F, Torres-Aleman I (2006) Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiol Aging 27:1250–1257PubMedCrossRef
166.
Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, Xu H (2001) Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 21:2561–2570PubMedPubMedCentralCrossRef
167.
Chung HY, Lee EK, Choi YJ, Kim JM, Kim DH, Zou Y, Kim CH, Lee J, Kim HS, Kim ND, Jung JH (2011) Molecular inflammation as an underlying mechanism of the aging process and age-related diseases. J Dent Res 90(7):830–840PubMedCrossRef
168.
Kao SY (2009) Rescue of alpha-synuclein cytotoxicity by insulin-like growth factors. Biochem Biophys Res Commun 385:434–438PubMedCrossRef
169.
Guan J, Krishnamurthi R, Waldvogel HJ, Faull RL, Clark R, Gluckman P (2000) N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats. Brain Res 859:286–292PubMedCrossRef
170.
Ebert AD, Beres AJ, Barber AE, Svendsen CN (2008) Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson’s disease. Exp Neurol 209:213–223PubMedCrossRef
171.
172.
Ribeiro MJDC (2014) Oxidative stress in Huntington’s disease knock-in striatal cells (Doctoral dissertation).
173.
174.
Li W, Quigley L, Yao DL, Hudson LD, Brenner M, Zhang BJ, Brocke S, McFarland H, Webster HD (1998) Chronic relapsing experimental autoimmune encephalomyelitis: effects of insulin-like growth factor-I treatment on clinical deficits, lesion severity, glial responses, and blood brain barrier defects. J Neuropathol Exp Neurol 57(5):426–438PubMedCrossRef
175.
176.
Teramoto S, Miyamoto N, Yatomi K, Tanaka Y, Oishi H, Arai H, Hattori N, Urabe T (2011) Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab 31(8):1696–1705PubMedPubMedCentralCrossRef
177.
Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA, Greig NH (2007) Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 203(2):293–301PubMedCrossRef
178.
179.
180.
Parsarathy V, Holscher C (2011) The novel GLP1 analogue, liraglutide, reduces inflammation in a mouse model of brain tissue injury. In Washington, DC: Society for Neuroscience Annual Meeting.
181.
Qin Z, Sun Z, Huang J, Hu Y, Wu Z, Mei B (2008) Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-β peptide (1–42). Neurosci Lett 444(3):217–221PubMedCrossRef
182.
183.
Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomers. J Clin Invest 122(4):1339–1353PubMedPubMedCentralCrossRef
184.
Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW, Tweedie D, Perry T, Mattson MP, Kapogiannis D, Sambamurti K (2010) GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer’s disease. J Alzheimers Dis 19(4):1205–1219PubMedPubMedCentralCrossRef
185.
Kim S, Moon M, Park S (2009 Sep 1) Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson’s disease. J Endocrinol 202(3):431–439PubMedCrossRef
186.
Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS (2008) Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson’s disease. J Neuroinflammation 5(1):1–9CrossRef
187.
188.
D’Amico M, Di Filippo C, Marfella R, Abbatecola AM, Ferraraccio F, Rossi F et al (2010) Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice. Exp Gerontol 45:202–207PubMedCrossRef
189.
190.
191.
192.
Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, Murphy MF, Natter HM, Norris FH, Rudnicki SA (1997) Effect of recombinant human insulin-like growth factor-I on progression of ALS: a placebo-controlled study. Neurology 49(6):1621–1630PubMedCrossRef
193.
Borasio GD, Robberecht W, Leigh PN, Emile J, Guiloff RJ, Jerusalem F, Silani V, Vos PE, Wokke JH, Dobbins T (1998) A placebo-controlled trial of insulin-like growth factor-i in amyotrophic lateral sclerosis. European als/igf-i study group. Neurology 51:583–586PubMedCrossRef
194.
195.
Sorenson E, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, Barkhaus PE, Bosch P, Boylan K, David WS, Feldman E (2008) Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 71(22):1770–1775PubMedPubMedCentralCrossRef
196.
Vincent AM, Mobley BC, Hiller A, Feldman EL (2004) Igf-i prevents glutamate-induced motor neuron programmed cell death. Neurobiol Dis 16:407–416PubMedCrossRef
Metadata
Title
Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions
Authors
Ambika Shandilya
Sidharth Mehan
Publication date
01-08-2021
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 8/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-021-05328-6

Other articles of this Issue 8/2021

Neurological Sciences 8/2021 Go to the issue

Original Article

Energy cost and psychological impact of robotic-assisted gait training in people with spinal cord injury: effect of two different types of devices

Brief Communication

Hereditary diffuse leukoencephalopathy with spheroids mimicking primary progressive aphasia: report of a Greek case

COVID-19

Impact of COVID-19 on chronic migraine treated with erenumab: a case report

Original Article

Epileptic olfactory auras: a clinical spectrum

Original Article

Male patients with neuromyelitis optica spectrum disorders: different clinical characteristics and worse steroid treatment response

Letter to the Editor

Effect of transfusion therapy on intracranial stenosis in a child with sickle cell anaemia